INTRODUCTION
A significant obstacle to effective chemotherapy of viral disease is the continued replication of a subtraction of the virus population despite the presence of the antiviral agent (viral breakthrough).
Even agents that are potent inhibitors in vitro (e.g. 3'-azidothymidine [AZT]) allow breakthrough viremia in vivo (1) . There are several possible mechanisms responsible for this viral breakthrough. Viral variants encoding drug resistance mutations may pre-exist within the virus population and emerge as the dominant replicating species when the selective pressure of an antiviral agent is applied. In the case of HIV-1, variants resistant to nucleoside and non-nucleoside reverse transcriptase inhibitors have readily emerged after drug selection in vitro and in vivo (3, 4, 6, 7, 8, 12, 14) . These resistant strains probably contribute to the breakthrough viremia and disease progression that has been observed in patients on long term antiretroviral therapy (2, 18) .
Another mechanism by which viral breakthrough can occur involves cellular heterogeneity with regard to drug uptake, activation or elimination. This 'cellular' drug resistance renders the antiviral agent ineffective in a subset of the host cell population. For example, the metabolism and antiretroviral activity of certain nucleoside analogs (e.g. AZT) is dramatically influenced by the growth and activation state of the host cell (15, 17) .
There are currently no experimental systems available to systematically quantitate and differentiate the mechanisms responsible for breakthrough replication of HIV-1 in the presence of various antiretroviral agents. There are also no published data available on the frequency with which drug-resistant mutants spontaneously exist within unselected virus populations. Such information is needed to design more effective combination antiviral therapies that minimize or eliminate viral breakthrough.
This report describes two novel recombinant HTV systems that allow the detection of rare virus-infected cells. In the first system a recombinant HTV encoding beta-galactosidase (HIV-LacZ) is used to study the antiretroviral effects of drugs that inhibit early stages of the HIV replicative cycle. This system uses recombinant HIV produced in COS cells after co-transfection of a plasmid encoding the defective HIV-LacZ genome with a plasmid encoding the complementing HTV genes necessary for the production of an infectious recombinant virus. The limited genetic heterogeneity of these recombinant viruses, however, does not allow an analysis of the contribution of drug-resistant variants to HIV breakthrough events. To achieve this, a second system was used in which recombinant virus was rescued from CD4 + cell lines by rescue with replication-competent 'helper' HTV. Since the defective virus depends upon the helper HTV for many of the proteins necessary for infectivity, the rescued defective genome carrying a reporter gene can serve as an indicator of the drug sensitivity and resistance of the replication-competent population used as the source of helper virus.
MATERIALS AND METHODS

Construction of recombinant proviral DNA
The HIV constructs encoding LacZ are shown schematically in Figure 1 . The HTV-gpt and HXB2env plasmids were provided by Kathleen Page (University of California, San Francisco, CA) (9) . The HIV-gpt plasmid contains an HXB2 provirus into which an SV40 promoter-gpt gene was inserted into the env region. The HXB2 env plasmid contains the HXB2 gpl60 gene driven by an SV40 promoter. The BH10 plasmid was obtained from F. Wong-Staal and R. Gallo (NCI, Bethesda, MD.). The CMV/HTV-gag-pol-env (CGPE-) plasmid was provided by A. Brodsky and A. Nienhuis (NIH, Bethesda, MD.) and contains a CMV promoter driving the expression of an HIV genome from which the LTRs and putative packaging sequence have been deleted (13) .
An infectious proviral clone of HIV-l(pHIV-l) was reconstructed from the HTV-gpt and BH10 plasmids by ligating the internal Sal 1-Bam HI fragment from BH10 into Sal 1 and Bam HI digested HIV-gpt. HIV(Bal 1-Bal 1)H4 LacZ and HIV(Bal 1-Bal l)CMVLacZ were made by digesting pHIV-1 with Bal I and inserting a 3.6 kb DNA fragment containing either the histone H4 promoter or the CMV promoter adjacent to the LacZ gene (16) . These constructs also had an SV40 origin of replication inserted into the plasmid backbone. The HTV(Bal I-Bam HI)SV40LacZ, HTV(Bal I-Bam HI)CMVLacZ and HTV(Bal IBam HI) CMVLaczpA(ro) constructs were prepared by digesting Production of 'plasmid derived' recombinant retroviruses All transfections and cell culture were performed in an approved BSL-2 facility with BSL-3 techniques. Plasmid DNA cotransfections into COS cells were performed as described by Page et al (9) . Supernatants from COS cells were collected 40 hours after transfection and assayed for infectious recombinant HIVLacZ virus by inoculating 2 X10 5 HeLa-T4 cells (5) with 0.1 ml of filtered (0.45 pm) supernatant. Cells were stained for betagalactosidase activity with X-gal 48 hours after infection as described (16) . To assay for infectious recombinant HIV-gpt virus, the infected HeLa-T4 cells were trypsinized and split 1:10 into gpt selective media as described (9) . Medium changes were performed every 3 days and colonies were counted 14 days postinfection after staining with 1% crystal violet in 10% formalin.
Production of cell lines containing defective HTV-gpt and HTV-LacZ
The H9/HIV-gpt cell line was prepared by infecting H9 cells with HTV-gpt followed by selection in gpt selective media. The HeLa-T4/HIV-LacZ cell line was prepared by calcium:phosphate cotransfection of HeLa-T4 cells witfi the HTV(Bal 1-Bam HI) SV40LacZ and PSV2GPT plasmids (10:1) followed by selection of clones in gpt selective media. Individual colonies were isolated, expanded and assayed for beta-galactosidase expression with Xgal staining (16) . Isolated colonies containing beta-galactosidase were infected with HlV-lms at an m.o.i. of 0.1 and five to seven days later the culture supernatant was harvested, filtered (0.45/im) and assayed for infectious HTV-LacZ by infecting HeLa-T4 cells with 0.1 ml of supernatant followed by staining for beta-galactosidase activity after 48 hours. One HeLa T4/HIVLacZ cell line consistently produced > 1 x 10 3 infectious HTVLacZ/ml of culture media after rescue infection with 
Rescue of defective retroviruses
Rescue of defective retroviruses from the H9/HTV*gpt cell line and the HeLa T4/ HTV-LacZ cell line were performed as described above except that the specific virus population used for rescue was varied to include known drug-resistant and drugsensitive viruses. Following each rescue infection, the resultant titer of HIV-LacZ or HTV-gpt was was determined and the inoculum used to infect HeLa-T4 cells was adjusted depending upon the number of infectious events to be analyzed.
RESULTS
Production and characterization of recombinant HTVs encoding beta-galactosidase
A previous study demonstrated the utility of murine retroviruses encoding beta-galactosidase in characterizing the activity of antiretroviral compounds (15) . To extend these studies to HTV we sought to develop an HTV based recombinant retrovirus containing a LacZ reporter gene. The strategy used to generate infectious recombinant HIV was similar to that previously described by Page et al. for the production of HTV-gpt (9) . A recombinant HIV plasmid encoding LacZ was co-transfected into COS cells with one or more complementing plasmids containing the HTV regulatory and structural genes necessary for production of infectious recombinant virus. The HTV-LacZ plasmids constructed are shown schematically in Figure 1 . In initial experiments, the HTV(Bal I-Bal I)H4LacZ plasmid was complemented with the HTV-gpt plasmid. Transfection of the HIV(Bal I-Bal I)H4LacZ plasmid without a complementing plasmid served as the control.
The titer of infectious HTV-LacZ produced by COS cell cotransfection was quantitated by counting the number of betagalactosidase positive HeLa-T4 cells per 35-cm 2 well following infection with 0.1 ml of COS cell supernatant. As shown in Table  I (Table I) .
Several other HTV-LacZ constructs were made in an attempt to increase the efficiency of virus production ( Figure 1 and Table  I ). In the HTV(Bal I-Bal I) CMVLacZ construct, the H4 promoter was replaced with a CMV promoter. Although this increased the intensity of X-gal staining of individual infected cells, the number of LacZ positive cells present was not increased (Table I) . Reducing the size of the HTV-LacZ construct by replacing the Bal I-Bam HI HTV fragment with CMVLacZ or SV40LacZ also did not improve the virus yield. However, use of CGPE-as the complementing plasmid increased the titer of several HIV LacZ constructs to as high as 1.5 x lO^ml (Table I) . Using CGPE-as the complementing plasmid, the HTV(Bal 1-Bam HI)SV4OLacZ construct was found to produce the highest titers of HTV-LacZ of all the constructs studied. To assess whether replicationcompetent virus had been generated by recombination during cotransfections of CGPE-and HTV(Bal I-Bam HI)SV40LacZ, 5 ml of COS cell supernatant containing 7.5 X10 3 infectious HTVLacZ was used to inoculate the MT-2 cell line. Culture of the MT-2 cells for one month failed to reveal any cytopathological evidence of replication-competent virus indicating that less than 1.33 X1O~4 of the infectious virus produced in this system is replication-competent. Nevertheless, the potential for production of replication-competent virus exists and all materials were handled in the same manner as infectious HTV-1.
Recombinant HTVs producing cytopathic effect
Some of the HTV-LacZ constructs shown in Figure 1 encode both LacZ and the envelope glycoproteins of HTV-1 (gpl20/41). When these viruses infect cells, expression of both LacZ and Gp 120/41 is possible. Expression of gpl20/41 in cells bearing CD4 produces cytopathology characterized by syncytium formation. Indeed, as shown in Figure 2A , when the HTV(Bal 1-Bal l)CMVLacZ plasmid, which encodes the HTV env gene, was cotransfected into COS cells with the HXB2env and HTV-gpt plasmids, the resultant virus produced occasional syncytia in Hela-T4 cells that also stained intensely with X-gal, indicating co-expression of LacZ and gp 120/41. In contrast, when the HTV(Bal 1-Bam HI)CMVLacZ plasmid, which does not contain the env gene, was transfected with the same complementing plasmids, the resultant virus produced LacZ positive HeLa-T4 Table I . The indicated plasmids were co-transfected into COS cells and the supernatant was assayed for infectious HTV-LacZ in HeLa-T4 cells as described in Materials and Methods. Use of recombinant HTVs to assess the activity of antiretroviral compounds The HTV-LacZ constructs described above have potential utility in determining the effects of antiretroviral compounds on early replicative events following HTV infection. For example, the inhibitory activity of AZT was examined by infecting HeLa-T4 cells with HTV(Bal I-Bam HT)SV4OLacZ (produced in COS cells after co-transfection with CGPE-) in the presence of increasing concentrations of AZT. The number of HeLa-T4 cells staining with X-gal was determined 48 hours after infection. Figure 3 shows that the concentration-dependent inhibitory activity of AZT could be readily demonstrated using LacZ expression as the indicator of retroviral infection. This initial study suggests that the antiretroviral activity of compounds can be rapidly screened with recombinant HIV-LacZ.
Use of HTV-gpt to study antiretroviral drug resistance While the retroviruses described above can quickly provide information about the antiviral activity of specific compounds, the limited genetic heterogeneity of these recombinant viruses does not permit the detection of rare drug resistant viral variants that might exist within a replication-competent viral population.
To overcome this limitation a system was needed that introduced the genetic heterogeneity of replication-competent viruses into the recombinant virus population. This was achieved by using 'helper' viruses to rescue the defective recombinant viruses described above.
To establish a system that would allow packaging of HTV-gpt by rescue with replication-competent HTV-1, the H9/HTV-gpt cell line containing an integrated HTV-gpt was produced by infection of H9 cells with HTV-gpt virus followed by selection in gpt selective media. This cell line was then superinfected with well characterized drug-sensitive and drug-resistant laboratory strains of HIV as schematically shown in Figure 4 . The strains chosen Rescue of the integrated defective virus produces recombinant virus which can be studied for drug resistance (see Table 0 ).
for diese studies were HTV-lnjB and a variant of HlV-lms that is highly resistant (> 100-fold) to the tetrahydroimidazo-(4,5,l-jk)(l,4)-benzodiazepine-2(lH)thione (TTBO) derivative R82150 (7, 11) . The TTBO-resistant virus encodes a single nucleotide change in reverse transcriptase causing a leucine to isoleucine mutation at amino acid 100 (7, 11) . Seven days after infection of H9/HTV-gpt with the TTBO-resistant and TTBOsensitive viruses, supernatants were harvested and used to infect HeLa -T4 cells in the presence and absence of l^M TTBO (~ 25 times the IC 50 ). Three days later the HeLa -T4 cells were split into gpt selective media and colonies were counted after 10 days. As shown in Table n , TTBO-resistant HTV-gpt was generated when HTV-gpt was rescued with TTBO-resistant HTV-1 msSimilarly, TTBO-sensitive HTV-gpt resulted from rescue with sensitive helper virus. These results demonstrate that the drug sensitivity phenotype of the rescued HTV-gpt reflects the phenotype of the helper virus.
To estimate the frequency of TTBO-resistant virus within an unselected population of replication competent HTV-1, the H9/HTV-gpt cell line was infected with a standard laboratory stock of HTV-lrjTB and the rescued virus was harvested 10 days later. This virus preparation was used to infect HeLa-T4 cells in the presence of 1/tM TTBO. Infection of HeLa-T4 with HTV-gpt generated by plasmid co-transfections of COS cells ('plasmid derived' virus) was performed in parallel. Table HI provides a summary of these results, which demonstrate that TTBO-resistant HIV breakthrough was approximately twenty times more frequent with the HTV-gpt virus generated by HTV-lrnB rescue as compared with plasmid-derived virus. This difference in TIBO breakthrough is likely due to the presence ofTTBO-resistant viral variants within the stock of HTV-lniB used for rescue. In contrast, virus packaged in COS cells contains viral proteins (e.g. reverse transcriptase) encoded by plasmids and thus drug-resistant variants are likely to be less frequent than in a genetically heterogenous replication-competent helper virus population such as HIV-1 ma-An alternative explanation for the observed difference in TIBO breakthrough is that packaging of virus in COS cells alters its TTBO susceptibility relative to virus packaged in H9 cells. However, control experiments have demonstrated no difference in the TIBO concentration-inhibition curves for COS cell-derived and H9-derived HTV-gpt except at the extreme end of the curve above the 99.5% inhibitory concentration. This difference in breakthrough at the far end of the concentrationinhibition curve is likely due to a higher frequency of high level TIBO-resistant variants in the HIV-gpt population produced by rescue with HTV-lrnB. If cellular-encoded resistance was the dominant mechanism responsible for HTV-gpt breakthrough, then the frequency of breakthrough would be similar for the two populations of HTV-gpt.
Production of 'rescued' recombinant HTV-1 encoding LacZ
Limitations of the HTV-gpt system presented above include the long time required for colony formation in gpt selective media (Figure 1 ). Therefore, a cell line containing an integrated HrV(BaU-BamHT)SV40LacZ was prepared as described in Materials and Methods. This cell line, HeLa T4/HTV-LacZ, was infected with unselected (TIBO-sensitive) and TIBO-resistant HrV-lnm and the drug sensitivity phenotype of the rescued virus was determined by infection of HeLa-T4 cells in the presence of 1 and 5 jtM TTBO, followed by X-gal staining 48 hours later. The results of this experiment, shown in Table IV , indicate that HeLa-T4/HTV-LacZ can be used to rapidly detect and quantitate drug-resistant variants within the rescuing population without the potential problem of RT chimerism.
DISCUSSION
We have previously reported the use of Moloney leukemia viruses (MLV) encoding LacZ to rapidly quantitate retroviral infection and its inhibition by antiretroviral compounds (15) . Extension of these studies to HTV required the construction of novel recombinant HTVs. To this end, we have constructed several HTV-based plasmids encoding LacZ that produce infectious recombinant virus when complemented with the necessary HTV structural and regulatory genes. The plasmid-derived recombinant HTV-LacZ system described here holds promise as a screening tool for the identification of compounds that inhibit any of the early steps in the HTV replicative process. For example, drugs that block viral attachment, penetration or reverse transcription could be identified with several of the recombinant viruses depicted in Figure 1 . In addition, agents that block syncytia formation could be identified using recombinant viruses mat also encode HIV env [e.g. HTV (Bal 1-Bal l)CMVLacZ]. Although we have not proven that integration is necessary for LacZ expression 48 hours after infection, we have not noted any reduction in the number of clusters of blue cells when the X-gal staining is delayed until 7 days after infection, indicating that most of the LacZ expression detected at 48 hours is stable. Advantages of this recombinant HIV-LacZ system include (1) rapid and unequivocal identification of virus-infected cells within 48 hours of infection, (2) quantitation of the antiretroviral effects of drugs on a single cycle of virus infection (3) use of a replication defective HTV which reduces but does not eliminate the potential for biohazard (i.e.recombination leading to replication competent HTV could occur) and (4) the ability to use several different target cell types for infection. In addition, the LacZ gene is a component of the virus genome therefore making LacZ expression a direct indicator of virus infection. Therefore, this system should complement other available indicator systems such as the HeLa CD4-LTR/3-gal cell line, which detects tat transactivation of an LTR driven beta-galactosidase gene (19) .
The virus titers obtained with the plasmid-derived recombinant HIV-LacZ systems (10 2 -lOVml) are lower than those obtained with recombinant MLV systems or other HIV systems (10, 13) . The absence of a packaging cell line as well as the greater complexity of HTV with respect to regulatory proteins and the RNA processing necessary for virion production may explain some of the differences in titer in comparison to MLV-based systems. Compared with other HTV-based systems, the lower titers of HIV-LacZ are likely related to differences in packaging and/or reverse transcription of viruses containing the LacZ gene. Despite lower titers, the incorporation of LacZ into recombinant HIV has the advantage of allowing very rapid assay without the need for prolonged propagation or manipulation of cells.
In addition to the use of defective viruses packaged in COS cells, we have also prepared defective recombinant HIV by rescue with replication-competent HIV. Helper virus rescue increases the recombinant virus titer and introduces the heterogeneity of replication-competent viruses into the recombinant virus population, allowing the detection of rare viral variants. This system is well suited for the analysis of resistance to antiretroviral agents active against the early stages of the retroviral infectious cycle.
Using this system with two different recombinant HTV-1 retroviruses we have been able to make preliminary conclusions concerning the nature of viral breakthrough events occurring in vitro. Data presented in Table II indicate that rescue of HTVgpt with characterized ITBO-sensitive and TTBO-resistant stocks of HIV IIIB produces HIV-gpt with the TIBO-sensitivity phenotype of the helper virus used for rescue. Thus, although HTV-gpt encodes RT and the rescued HTV-gpt virus is likely to be chimeric with respect to origin of RT, the HIV-gpt phenotype reflects the TIBO-resistance of the viral stock when well characterized stocks of virus are used for rescue.
HTV-gpt generated by rescue with an unselected population of HTV-lmB resulted in colony formation in the presence of 1TBO at a much greater frequency than virus packaged in COS cells. This difference was not due to intrinsic differences in drug sensitivity when virus is produced in two different cell types (COS cells as opposed to H9 cells) as demonstrated by control experiments which detected no differences in the TBO sensitivity of the two virus populations except at TIBO concentrations producing greater man 99.5% inhibition. Therefore, this difference is presumed to be secondary to a higher frequency of TIBO-resistant variants within the helper virus population used for rescue in comparison to the 'plasmid-derived' virus packaged in COS cells. The exact frequency of these TIBO-resistant variants in the unselected helper virus population is difficult to determine with the HTV-gpt system because of the chimerism of RT. Thus, the frequency of TTBO-resistant variants determined with the HIV-gpt system is likely to be an underestimate, representing the minimum frequency of TIBO-resistant variants in the helper virus population. Similar experiments with recombinant virus rescued from the HeLa T4/HTV-LacZ cell line are not confouded by the production of RT by the recombinant genome. In fact, HTV-LacZ rescued from this cell line had a 4-5 fold higher frequency of TIBO-resistant virus. This difference in the frequency of TIBO-resistant HTV-gpt and TIBO-resistant HIV-LacZ after rescue with same helper virus (HTV-IJUB) may in part be explained by the RT chimerism of the HTV-gpt virus. That is, drug-sensitive RT molecules encoded by the HIV-gpt genome can dilute or negate the effects of co-packaged drugresistant RT encoded by the helper virus.
Additional experiments have used an identical approach to study HIV breakthrough in in the presence of AZT (data not shown). These experiments utilized the same plasmid-derived and HTV-IJUB rescued virus stocks used in the TIBO breakthrough experiments described above. However, unlike the TIBO experiments, there was no difference in HIV breakthrough in the presence of 1/iM, 5jtM or 10/tM AZT when plasmid-derived virus was compared with virus produced by rescue with unselected HTV-lnn,. The differences between TIBO and AZT breakthrough in this system is consistent with the hypothesis that we are detecting TIBO-resistant virus in the unselected helper virus population, since only a single point mutation is necessary for TIBO resistance. In contrast, spontaneous AZT resistance in an unselected virus population is likely to occur at a much lower frequency since multiple mutations in RT are necessary to induce high level AZT resistance (4) . The sensitivity of the current assay does not allow detection of spontaneously AZTresistant viruses in an unselected laboratory stock of HTV-IUJB. Efforts to increase the sensitivity of these assays are currently underway.
A particular advantage of the use of recombinant viruses to analyze breakthrough events in the presence of antiviral agents is the ability to study a single cycle of infection. This allows detection of breakthrough events in an unselected population without concern about spread of the virus and amplification of breakthrough events following exposure to the antiviral agent. Using recombinant viruses we can estimate that at least .001 of an unselected HIV population is spontaneously resistant to TIBO R82150.
